The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea-Reference-Cited by-同舟云学术

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

Published:2022 Issue:14 Volume:37 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Choi Myeong Geun¹²^ORCID,Ye Byong Duk³^ORCID,Yang Suk-Kyun³^ORCID,Shim Tae Sun¹^ORCID,Jo Kyung-Wook¹^ORCID,Park Sang Hyoung³^ORCID

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mokdong Hospital, College of Medicine, Ewha Womans University, Seoul, Korea.

3. Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Funder

National Research Foundation of Korea

Publisher

Korean Academy of Medical Sciences

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2022.37.e107

Reference20 articles.

1. Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy

2. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor